 |
Cancer Cell Market |
The Cancer Cell Market differs from normal cells in that a succession of mutations can cause a normal cell to continue to expand and divide out of control, resulting in the formation of cancerous cells.
Cancer cells, unlike regular cells, have the potential to move or infiltrate surrounding tissues and so spread to different parts of the body, whereas normal cells stay in the area where they started.
A cascade of genetic and epigenetic alterations causes cancer cells to form in the human body.
Some of these changes can be inherited or, more commonly, triggered by carcinogens (substances that cause cancer), such as tobacco.
In 2020, the global cancer cell market is predicted to be worth US$ 8,525.5 million, growing at a CAGR of 8.20 percent over the forecast period (2020-2027).
During the projected period, the worldwide cancer cell market is expected to rise due to the rising prevalence of cancers such as lung cancer, breast cancer, and others.
For example, according to a World Health Organization report issued in 2018, cancer is the second biggest cause of mortality in individuals worldwide, accounting for about 9.6 million fatalities in 2018.
Furthermore, the market is predicted to increase due to significant firms focusing on inorganic tactics such as mergers and acquisitions to offer innovative targeted cell treatments for the treatment of cancer patients.
Pfizer, for example, announced a merger with Allogene in 2018 to develop investigational CAR-T cell therapy for cancer treatment.
Coronavirus's Impact on the Global Cancer Cell Market (COVID-19)
COVID-19 has expanded to over 100 nations since its outbreak in December 2019, prompting the World Health Organization to designate it as a public health emergency.
According to a study from the World Health Organization, the coronavirus (COVID-19) has infected about 67 million people worldwide as of December 7, 2020.
Key Players
0 Comments